Recombinant Human Galectin-3C Protein, CF

When Recombinant Human Integrin alpha 5 beta 1 (Catalog # 3230-A5) is coated at 1 μg/mL (100 μL/well), Recombinant Human Galectin-3C (Catalog # 10110-GA) binds with an ED50 of 1‑6 μg/mL

2 μg/lane of Recombinant Human Galectin‑3C was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 14-18 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Galectin-3C Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Integrin alpha 5 beta 1 Recombinant Human Integrin alpha 5 beta 1 (Catalog # 3230-A5) is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Human Galectin-3C that produces 50% of the optimal binding response is 1-6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human Galectin-3C protein
  Gly108-Ile250
• Accession #: P17931
• N-terminal Sequence: Gly108
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 16 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 14-18 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HEPES, NaCl, TCEP, PEG and Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Galectin-3C Protein, CF

• Galectin-3C

Background

Human Galectin-3, also known as Mac-2, L29, CBP35, and epsilon BP, is classified as a chimeric member of the Galectin superfamily and contains one carbohydrate recognition domain (CRD) linked to a nonlectin domain (1, 2). The truncated form, Galectin-3C, which consists of the carboxy-terminal amino acid residues of Galectin-3 and lacks the N-terminal domain, has been shown to inhibit tumor growth and metastasis (3, 4). Within this region, human Galectin-3C shares 87% and 83% amino acid (aa) sequence identity with mouse and rat Galectin-3C, respectively. Galectin-3C has been found to interact with Integrin beta 1 in Hela cell lateral mobility assays (5). It can also be found endogenously attached to cell surface of neutrophils (6). Galectin-3C has been shown to enhance the activity of cancer therapy drugs as well as inhibiting tubule formation during angiogenesis (3).

1. Robertson, M.W. et al. (1990) Biochemistry 29:8093.
2. Elola, M.T. et al. (2007) Cell. Mol. Life Sci. 64:1679.
3. Mirandola, L. et al. (2011) PloS One 6:e21811.
4. John, C.M. et al. (2003) Clin. Cancer Res. 9:2374.
5. Yang, E.H. et al. (2017) PLoS ONE 12:e0184378.
6. Sundqvist, M. et al. (2018) J. Leukoc. Biol. 103:341.

Bioinformatics

• Uniprot:
  • P17931(Mouse)